Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research

Aclarion, Inc. has established a commercial agreement with Weill Cornell Medicine to bring its Nociscan diagnostic technology to a clinical trial at Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center. The trial, entitled "A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate (BMAC) for Osteoarthritis and Degenerative Disc Disease," will investigate how the dose and quantity of BMAC affects patient-reported functional outcomes and pain. A subset of spine patients selected through clinical evaluation by Principal Investigator Jaspal Ricky Singh, MD, will be eligible for Nociscan assessment as part of this research initiative.

Dr. Singh, Vice Chair and Director of Interventional Spine at Weill Cornell Medicine, emphasized the alignment between the trial's focus and Nociscan's capabilities, stating, "Our pioneering research into discogenic low back pain and cBMA (concentrated bone marrow aspirate) is an ideal opportunity to utilize the insights provided by Nociscan." The technology represents a significant development in addressing chronic low back pain, a global healthcare problem affecting approximately 266 million people worldwide suffering from degenerative spine disease and low back pain according to research published in Global Spine Journal.

Nociscan is the first evidence-supported Software-as-a-Service platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology objectively quantifies chemical biomarkers demonstrated to be associated with disc pain through a cloud-based system that receives magnetic resonance spectroscopy data from MRI machines. Proprietary algorithms then analyze biomarker data to indicate if a disc may be a source of pain, providing critical insights when used alongside other diagnostic tools.

The integration of Nociscan into Weill Cornell Medicine's research represents an important step in validating the technology's clinical utility within a prestigious academic medical center known for innovation in spine care. This collaboration may help establish more standardized approaches to identifying pain generators in degenerative spine conditions, potentially improving treatment targeting and patient outcomes. For more information about Aclarion and its technology, please visit https://www.aclarion.com.

The commercial agreement follows Aclarion's ongoing efforts to expand clinical adoption of its diagnostic platform, which has shown potential to improve pain and function outcomes when all Nociscan-positive discs are treated according to previous research. As spine medicine continues to evolve toward more personalized treatment approaches, technologies that provide objective data about pain sources could play an increasingly important role in clinical decision-making. The Weill Cornell Medicine trial represents a significant opportunity to gather additional evidence about Nociscan's utility in complex spine cases being managed through multidisciplinary approaches.